Complement component C5 antibodies

Patent metadata

Field	Value
Publication number	US-9701743-B2
Application number	US-201514626514-A
Country	US
Kind code	B2
Filing date	Feb 19, 2015
Priority date	Feb 20, 2014
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.

First claim

We claim:

1. An anti-C5 antibody, wherein the antibody binds to C5 and inhibits complement dependent hemolysis, but does not block C5a formation, wherein the antibody comprises a first amino acid sequence and a second amino acid sequence, further wherein:
(a) the first sequence comprising;
(i) a CDR1 selected from the group consisting of SEQ ID NOs:13, 19, 25, 31, 37 and 43;
(ii) a CDR2 selected from the group consisting of amino acids sequence GTS (SEQ ID NOS: 14 and 20), SGS (SEQ ID NO: 26), RTS (SEQ ID NO: 32), YTS (SEQ ID NO: 38), and WAS (SEQ ID NO: 44); and
(iii) a CDR3 selected from the group consisting of SEQ ID NOs:15, 21, 27, 33, 39 and 45; and

(b) the second sequence comprising
(i) a CDR1 selected from the group consisting of SEQ ID NOs:16, 22, 28, 34, 40 and 46;
(ii) a CDR2 selected from the group consisting of SEQ ID NOs:17, 23, 29, 35, 41 and 47; and
(iii) a CDR3 selected from the group consisting of SEQ ID NOs:18, 24, 30, 36, 42 and 48.

2. The antibody of claim 1 , wherein the antibody blocks C5 binding to human Complement Component 6 and/or 7.

3. The antibody of claim 1 , wherein the antibody inhibits formation of membrane attack complex (MAC).

4. The antibody of claim 1 , further comprising a heavy chain and a light chain wherein:
the light chain comprises an amino acid sequence identical to a sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, and 11; and
the heavy chain comprises an amino acid sequence identical to a sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, and 12.

5. The antibody of claim 1 , wherein the antibody comprises a light chain and a heavy chain variable domain selected from the light chain and heavy chain variable sequences: SEQ ID NO:1/SEQ ID NO:2; SEQ ID NO:3/SEQ ID NO:4; SEQ ID NO:5/SEQ ID NO:6; SEQ ID NO:7/SEQ ID NO:8; SEQ ID NO:9/SEQ ID NO:10; SEQ ID NO:11/SEQ ID NO:12; and SEQ ID NO:3/SEQ ID NO:10.

6. The antibody of claim 1 , wherein the antibody is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

7. The antibody of claim 6 , wherein the antibody is an antibody fragment and the antibody fragment is a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

8. The antibody of claim 6 , wherein said antibody is of the IgG1-, IgG2-IgG3- or IgG4-type.

9. The antibody of claim 8 , wherein the antibody is of an IgG1-type.

10. The antibody of claim 1 , wherein the antibody is coupled to a labelling group.

11. The antibody of claim 10 , wherein the labelling group is an optical label, radioisotope, radionuclide, an enzymatic group, and a biotinyl group.

12. A method for treating or reducing the occurrence of an indication associated with complement activation in a patient in need thereof;
comprising administering to said patient an effective amount of the antibody of claim 1 ;

and thereby treating or reducing the occurrence of the indication.

13. The method of claim 12 , wherein the condition is an ocular condition.

14. The method of claim 13 , wherein the condition is age-related macular degeneration.

Assignees

• Allergan Inc

Inventors

• Baciu Peter C
• Liang Yanbin
• Guu Jason
• Bernett Matthew
• Muchhal Umesh
• Desjarlais John

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title